Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Scientific, a medical device company, has announced that the FDA has approved the Express SD Renal Monorail premounted stent system for use as an adjunct to percutaneous transluminal renal angioplasty in certain lesions of the renal arteries.
Subscribe to our email newsletter
According to the company, the Express SD Renal stent is designed specifically for treatment of the renal arteries by incorporating additional connections in the proximal end of the stent, which are intended to provide excellent support, especially in lesions occurring at the opening of the renal artery.
Based on Maverick Monorail balloon catheter technology and Tandem Architecture stent design, the Express SD Renal stent is designed to provide strength, precision and deliverability, the company said.
The company claims that the Express SD system is the first low-profile, pre-mounted stent approved for use in renal arteries in the US. It is also said to be the only FDA-approved renal stent designed to provide additional proximal end support.
Jim Tobin, president and CEO of Boston Scientific, said: FDA approval for the Express SD Renal stent is an important step in providing physicians evidence-based technology to facilitate the management of renal artery disease. With the addition of the Express SD Renal stent, Boston Scientific can now offer customers the industry’s leading portfolio of products for endovascular treatment of this disease.